Johnson & Johnson to Acquire Cancer-Treatment Developer Ambrx for $2 Billion

[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…

J&J to acquire cancer drug developer Ambrx Biopharma for $2 billion

[ad_1] An entry sign to the Johnson & Johnson campus shows their logo in Irvine, California on August 28, 2019. Mark Ralston | AFP | Getty Images Johnson & Johnson…

Johnson & Johnson to Acquire Cancer-Treatment Developer Amrbx for $2B

[ad_1] Johnson & Johnson will acquire cancer-treatment developer Ambrx Biopharma in a $2 billion cash deal. The pharmaceutical giant said Monday that the deal to acquire all shares of Ambrx…